| Literature DB >> 34188789 |
Haoran Zhao1, Peng Wang1, Haishi Liu1, Yueyang Li1, Qian Luo1, Man Li1, Yubao Zhang1, Zengfu Song1,2.
Abstract
Colon cancer is the third most frequent cancer in the world and is mainly adenocarcinoma in terms of pathological type. It has been confirmed that the dysregulation of RNA-binding proteins (RBPs) significantly participates in the occurrence and development of numerous malignant tumors. Therefore, we analyzed the RBPs associated with colon adenocarcinoma (COAD) to assess their possible biological effects and prognostic value. A total of 398 COAD tissue datasets and 39 normal tissue datasets were retrieved from the TCGA data resource and screened out the RBPs, which are differentially expressed between tumor tissues and nontumor tissues. Then, bioinformatics analyses based on smart medical big data were conducted on these RBPs. Overall, 181 differentially expressed RBPs were uncovered, consisting of 121 upregulated RBPs and 60 downregulated RBPs. Finally, we selected 7 prognostic-related RBPs with research prospects and constructed a prognostic model according to the median risk score. There were remarkable differences in OS between the high-risk and low-risk groups. In addition, the performance of the prognostic model was evaluated and verified with other COAD patient data in the TCGA database. The results showed that the area under the ROC curve (AUC) for the train group was 0.744 and the one for the test group was 0.661, confirming that the model assesses patients' prognosis to some extent. And based on 7 hub RBPs, we constructed a nomogram as a reference for evaluating the survival rate of COAD patients.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34188789 PMCID: PMC8192207 DOI: 10.1155/2021/5536330
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 2.682
Figure 1(a) Heat map and (b) volcano plot of differentially expressed RBPs in colon adenocarcinoma.
GO and KEGG enrichment analysis of differently expressed RBPs.
| GO term |
| |
|---|---|---|
|
| ||
| Biological processes (BP) | Regulation of translation | 3.22 |
| Regulation of cellular amide metabolic process | 9.25 | |
| Regulation of mRNA metabolic processing | 3.42 | |
| Regulation of mRNA processing | 1.30 | |
| Negative regulation of translation | 2.26 | |
| Regulation of RNA splicing | 2.48 | |
| Defense response to virus | 1.37 | |
| Response to virus | 2.55 | |
|
| ||
| Cellular component (CC) | Endolysosome membrane | 7.73 |
| Endolysosome | 2.39 | |
| Cytoplasmic ribonucleoprotein granule | 0.000335342 | |
| Ribonucleoprotein granule | 0.000422761 | |
|
| ||
| Molecular function (MF) | mRNA 3′-UTR binding | 4.75 |
| mRNA 3′-UTR AU-rich region binding | 2.24 | |
| AU-rich element binding | 4.02 | |
| Double-stranded RNA-binding | 1.52 | |
| Transition regulator activity | 4.76 | |
|
| ||
| KEGG pathway | Progesterone-mediated oocyte maturation | 0.00145067 |
| Toll-like receptor signalling pathway | 0.00167211 | |
| Oocyte meiosis | 0.00302753 | |
|
| ||
|
| ||
| Biological processes (BP) | ncRNA metabolic process | 6.50 |
| ncRNA processing | 2.15 | |
| Nucleic acid phosphodiester bond hydrolysis | 1.50 | |
| Ribonucleoprotein complex biogenesis | 3.07 | |
| RNA phosphodiester bond hydrolysis | 7.97 | |
| RNA localization | 3.61 | |
| Ribosome biogenesis | 8.39 | |
|
| ||
| Cellular component (CC) | Cytoplasmic ribonucleoprotein granule | 3.33 |
| Ribonucleoprotein granule | 5.90 | |
| Preribosome | 2.66 | |
| P granule | 4.62 | |
|
| ||
| Molecular function (MF) | Catalytic activity, acting on RNA | 3.54 |
| Nuclease activity | 4.55 | |
| Ribonuclease activity | 4.55 | |
| mRNA 3′-UTR binding | 4.82 | |
| Catalytic activity, acting on tRNA | 8.69 | |
|
| ||
| KEGG pathway | Ribosome biogenesis in eukaryotes | 8.34 |
| RNA transport | 5.55 | |
| mRNA surveillance pathway | 1.00 | |
| RNA degradation | 3.86 | |
Figure 2Protein interaction (PPI) network: (a) PPI network of differently expressed RBPs and Key Module, (b) Key Module 1 and (c) Key Module 2. Green circles: downregulation with a fold change of more than 4; red circles: upregulation with a fold change of more than 4.
Figure 3RBPs related to the prognosis of the train group identified by univariate COX regression analysis.
Figure 4RBPs related to prognosis identified by multivariate COX regression analysis.
Figure 5Protein expression in normal tissues and COAD in hub genes related to prognosis verified by HPA database. (a) TDRD5. (b) LIN28B. (c) PNLDC1. (d) TDRD7. (e) LRRFIP2.
Figure 6Risk score analysis of the prognostic model of COAD training group patients in the TCGA cohort. (a) Survival analysis according to risk score; (b) ROC analysis; (c) heat map and survival status.
Figure 7Risk score analysis of the prognostic model of COAD test group patients in the TCGA cohort. (a) Survival analysis according to risk score; (b) ROC analysis; (c) heat map and survival status.
Figure 8The prognostic value of different clinical parameters through univariate analysis (P < 0.01).
Figure 9The prognostic value of different clinical parameters through multivariate analysis (P < 0.01).
Figure 10Nomogram for predicting 1-, 3-, and 5-year OS of COAD patients.